Journal article
Recombinant factor VIIa concentrate versus plasma‐derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors
Abstract
BACKGROUND: In people with haemophilia, therapeutic clotting agents might be recognised as a foreign protein and induce anti-factor VIII antibodies, known as 'inhibitors'. Drugs insensitive to such antibodies, either recombinant or plasma-derived, are called factor VIII 'by-passing' agents and used for treatment of bleeding in people with inhibitors.
OBJECTIVES: To determine the clinical effectiveness of recombinant factor VIIa concentrate …
Authors
Matino D; Makris M; Dwan K; D'Amico R; Iorio A
Journal
Cochrane Database of Systematic Reviews, Vol. 2020, No. 12,
Publisher
Wiley
DOI
10.1002/14651858.cd004449.pub4
ISSN
1361-6137